Epcoritamab
As of the edition of 20 October 2026, Epcoritamab is an antibody: marketed, first approved in 2023 (US); acts on CD3D, CD3E and CD3G and 1 more; US protection ends in 2035.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Antibody
- Brand name
- Epkinly
- First approved
- 19 May 2023 (US)
- Approvals on record
- 7 in 4 regions
- Holder of the most recent approval
- AbbVie; 4 holders in all
- Registered trials
- 60, 3 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Infections; Heart and blood vessels; Nervous system
US protection
US protection ends in 2035.
US protection ends in 2035, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Merus. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Epcoritamab.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 0 |
| Phase 1 | 7 | 0 | 7 | 0 |
| Phase 2 | 45 | 0 | 41 | 3 |
| Phase 3 | 6 | 0 | 6 | 0 |
| All trials | 60 |